Literature DB >> 35663535

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab.

Fadi Haddad1, Naval Daver1.   

Abstract

Entities:  

Keywords:  AML; CD47; MDS; azacitidine; magrolimab

Year:  2021        PMID： 35663535      PMCID： PMC9153253          DOI： 10.36401/JIPO-21-X2

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN： 2590-017X


× No keyword cloud information.
  40 in total

1.  Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Authors:  Mark P Chao; Siddhartha Jaiswal; Rachel Weissman-Tsukamoto; Ash A Alizadeh; Andrew J Gentles; Jens Volkmer; Kipp Weiskopf; Stephen B Willingham; Tal Raveh; Christopher Y Park; Ravindra Majeti; Irving L Weissman
Journal:  Sci Transl Med       Date:  2010-12-22       Impact factor: 17.956

Review 2.  Current and emerging strategies for management of myelodysplastic syndromes.

Authors:  Caner Saygin; Hetty E Carraway
Journal:  Blood Rev       Date:  2020-12-27       Impact factor: 8.250

Review 3.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

5.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  How we treat higher-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Corey Cutler
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

8.  CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Authors:  Ravindra Majeti; Mark P Chao; Ash A Alizadeh; Wendy W Pang; Siddhartha Jaiswal; Kenneth D Gibbs; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

9.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

Review 10.  New directions for emerging therapies in acute myeloid leukemia: the next chapter.

Authors:  Naval Daver; Andrew H Wei; Daniel A Pollyea; Amir T Fathi; Paresh Vyas; Courtney D DiNardo
Journal:  Blood Cancer J       Date:  2020-10-30       Impact factor: 11.037
View more
  3 in total

Review 1.  Drugging the efferocytosis process: concepts and opportunities.

Authors:  Parul Mehrotra; Kodi S Ravichandran
Journal:  Nat Rev Drug Discov       Date:  2022-06-01       Impact factor: 112.288

Review 2.  Targeting macrophages in hematological malignancies: recent advances and future directions.

Authors:  Wei Li; Fang Wang; Rongqun Guo; Zhilei Bian; Yongping Song
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168

Review 3.  The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.

Authors:  Xiaohuan Peng; Xiaofeng Zhu; Tianning Di; Futian Tang; Xiaojia Guo; Yang Liu; Jun Bai; Yanhong Li; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.